Replies to post #214854 on Biotech Values

[MadCityCyclone]

I think they are over leveraged and will be forced to reorganize, in some manner. They should certainly cancel their dividend.

[biomaven0]

TEVA's CGRP migraine drug is decent, but they screwed up by not acquiring a PVR for it. So I'm assuming they'll be second to market after AMGN - still should be a good drug for them.

The time to buy them might be after they cut their dividend.

Peter